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osting by EAbstract Aims: Prevalence of hypogonadism is largely unknown in the general population and
population of diabetics in Arab countries including Jordan. This study was conducted to determine
the prevalence of hypogonadism among men with type 2 diabetes in Jordan and determine its asso-
ciated factors.
Methods: This cross-sectional study included a total of 1049 consecutive men with type 2 diabetes
who attended the National Center for Diabetes, Endocrinology and Genetics (NCDEG) in
Amman, Jordan, in the period from August 2008 to February 2009. Data were collected from med-
ical records and using a pre-structured questionnaire. Clinical characteristic, anthropometric mea-
surements and laboratory measurements were obtained. Hypogonadism was deﬁned as total
testosterone <3 ng/ml.
Results: Overall, 36.4% of patients with diabetes had total testosterone level <3 ng/ml and 29%
had symptoms of androgen deﬁciency. Of those with serum testosterone level <3 ng/ml, 80.2%ress: Sultan Bin Abdulaziz
iyadh 11536, Saudi Arabia.
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A.A. Alhayek et al.32had symptoms of androgen deﬁciency. About 16.9% of those with serum testosterone level <3 ng/
ml had primary hypogonadism and 83.1% had secondary hypogonadism. Age, monthly income of
less than 500 JD, obesity, and neuropathy were signiﬁcantly associated with low serum total testos-
terone level.
Conclusions: The prevalence of hypogonadism among men with type 2 diabetes in Jordan is high.
This urgently calls for implementing early and universal screening programs irrespective of symp-
toms of androgen deﬁciency to detect those who have low serum total testosterone level at any early
stage and to supplement testosterone accordingly.
 2011 International Journal of Diabetes Mellitus. Published by Elsevier Ltd. All rights reserved.1. Introduction
The association between hypogonadism and diabetes mellitus
has recently received considerable attention [1,2]. Investigators
have highlighted the potential metabolic consequences of tes-
tosterone decline, showing a potential role of low testosterone
on age-associated metabolic changes such as abdominal obes-
ity [3], diabetes and markers of prediabetes [4,5].
Most studies among men with diabetes had deﬁned hypo-
gonadism solely on the basis of testosterone levels [5]. Symp-
toms of hypogonadism have rarely been considered in
combination with biochemical testosterone deﬁciency [6].
There is an interest in understanding the co-occurrence of
symptoms of low testosterone, as well as low testosterone level,
because the clinical signiﬁcance of a low testosterone level
alone is unclear [7]. Total testosterone concentrations are
determined, to a large extent, by circulating sex hormone-bind-
ing globulin (SHBG) concentrations. In the blood of normal
men, 44% of total testosterone is bound to SHBG, 2% is un-
bound [free testosterone] and 54% circulates bound to albumin
and other proteins [8].
It is not known whether the lower testosterone levels in dia-
betics are associated with changes in luteinizing hormone (LH)
and follicular stimulating hormone (FSH). Previously pub-
lished data shows that the commonest form of gonadal dys-
function was hypogonadotropic hypogonadism [9]. Ando
et al. [10] reported low total testosterone and normal LH levels
in diabetics, whereas Ali et al. [11] found that subjects with dia-
betic neuropathy had low testosterone and high LH and FSH
levels.
The prevalence of hypogonadism is largely unknown in the
general population and the population of diabetics in Arab
countries, including Jordan. This study was conducted to
determine the prevalence of hypogonadism among men with
type 2 diabetes in Jordan and its associated factors.2. Methods
2.1. Subjects
This study comprised a total of 1049 consecutive men with
type 2 diabetes who attended the National Center for Diabe-
tes, Endocrinology and Genetics (NCDEG) in Amman, Jor-
dan, between August 2008 and February 2009. The study
was approved by the ethical committee of the NCDEG and
all patients gave verbal consent to participate in the study.
The sample size of 1049 yielded a power of more than 80%
at the level of conﬁdence of 95%, and a margin of error of
5%.2.2. Data collection
During the patients’ visits, their demographic characteristics
were collected using a pre-structured questionnaire. Data re-
lated to the duration of diabetes, medications and clinical his-
tory, including the presence of neuropathy, retinopathy and
coronary artery disease, were abstracted from medical records.
Study participants were asked to complete an Androgen Deﬁ-
ciency in Ageing Male (ADAM) questionnaire. This question-
naire has 88% sensitivity and 60% speciﬁcity [12]. A positive
response is based on a decrease in libido or the strength of
erections, or any three nonspeciﬁc questions that may include
a decrease in muscle strength, fatigability, mood changes and
loss of height.
2.3. Measurements
Weight and height were measured, and body mass index (BMI)
was computed by dividing the weight in kilograms by the
square of height in meters. Blood pressure was measured using
a standardized sphygmomanometer. A trained nurse per-
formed the procedure while the subject was in a sitting posi-
tion, with the arm at the level of the heart and after 5 min rest.
A venous blood sample (20 ml) was drawn between 8:00
and 10:00 AM after an overnight fast. Blood was withdrawn
from the cubital fossa and/or dorsum of the hand veins from
each participant, using a disposable syringe. It was injected
in the plain and CBC tube; the specimen immediately centri-
fuged, and serum was aliquoted and stored at 20 C for total
testosterone, free testosterone, SHBG, FSH, LH and prolactin
(PRL), HbA1c, total cholesterol, HDL cholesterol, LDL cho-
lesterol and triglyceride. Laboratory technicians were blinded
to participants’ characteristics. Total testosterone was assessed
using radioimmunoassay. Free testosterone was assessed using
Axsym, which is based on a microparticle enzyme immunoas-
say. SHBG was tested by means of an immunochemilumino-
metric assay. LH, FSH and prolactin were measured by
chemiluminescent immunometric assays. Glycosylated hemo-
globin (HbA1c) was analyzed using a high-performance liquid
chromatography (HPLC) method (Bio-Rad). Information
concerning HbA1c was adopted from tests made in the
NCDEG lab. Total cholesterol, triglyceride, HDL and LDL
were assayed through the automated spectrophotometer, enzy-
matic colorimetric method, COBAS INTEGRA using com-
mercial kits supplied by Roche Diagnostics.
2.4. Deﬁnitions
In our study, hypogonadism was deﬁned as total testosterone
<3.0 ng/ml. Symptomatic androgen deﬁciency was deﬁned
Table 1 Socio-demographic, clinical and relevant character-
istics of study participants.
Variable n (%)
Age (years), mean (SD) = 52.6 (11.2)
30–39 178 (16.3)
40–49 242 (22.2)
50–59 299 (27.5)
60–70 370 (34.0)
Education
Less than university 475 (43.6)
University education 614 (56.4)
Occupation
Employed 287 (43.3)
Not employed 713 (67.6)
Income (JD)*
<500 JD 545 (50)
P500 JD 544 (50)
Body mass index (kg/m2), mean (SD) = 29.9 (5.2)
<25 kg/m2 148 (16.9)
Overweight 428 (39.3)
Obese 477 (43.8)
Smoking
Non 282 (25.9)
Past 325 (29.8)
Current 482 (44.3)
Hypertension 902 (82.8)
Dyslipidemia 1007 (92.5)
HbA1c, mean (SD) = 8.3 (1.7)
HbA1c 6 7 232 (21.3)
HbA1c > 7 857 (78.7)
Duration of diabetes (years), mean (SD) = 8.1 (6.1)
65 503 (46.2)
6–10 273 (25.1)
>10 313 (28.7)
Diabetic retinopathy
No diabetic retinopathy 369 (33.9)
Non proliferative diabetic retinopathy 617 (56.7)
Proliferative diabetic retinopathy 103 (9.5)
Diabetic nephropathy 383 (35.2)
Diabetic nephropathy 404 (317)
* 1 JD = 1.41$.
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sponse to ADAM questionnaire. Primary hypogonadism was
deﬁned as LH >10MIU/ml with total testosterone <3.0 ng/
ml, while secondary hypogonadism was deﬁned as LH
610MIU/ml with total testosterone <3.0 ng/ml.
The diagnosis of DM was based on the American Diabetes
Association (ADA) criteria [13]. Nephropathy as diagnosed by
the nephrologists (the presence of either microalbuminuria
which is deﬁned as, the presence of microalbuminuria P30–
299 mg/24 h urine collection sample or the presence of macro-
albuminuria P300 mg/24 h urine collection sample) [14] was
obtained from the patient’s record. Retinopathy was deﬁned
according to the American Academy of Ophthalmology
(AAO) [15]. Patients were classiﬁed into non proliferative dia-
betic retinopathy (NPDR) and proliferative diabetic retinopa-
thy (PDR).
Overweight was deﬁned as BMI 25–29.9 kg/m2, and obesity
was deﬁned as BMI P30 kg/m2. Among type 2 diabetic pa-
tients, lipid levels were considered as abnormal according to
ADA criteria [16]. Hypercholesterolemia refers to a total cho-
lesterol level P200 mg/dl. HDL was considered low when the
level was <40 mg/dl. LDL was considered high when the level
P100 mg/dl. Hypertriglyceridemia was considered high when
TG level was P150 mg/dl. Dyslipidemia was considered pres-
ent when one or more of the previous abnormalities were
found in serum lipids, or if the patient was receiving medica-
tion for any of the above conditions.
Among the diabetic patients, hypertension was deﬁned
according to ADA criteria 2007 [13]. Coronary heart disease
(CHD) was deﬁned as a previous diagnosis of coronary artery
disease (CAD) by angiography or ECG, or in terms of current
treatment for CAD. Patients with HBA1c <7% were consid-
ered controlled [13].
2.5. Statistical analysis
Statistical analysis was conducted using the Statistical Package
for Social Sciences (SPSS version 15). Data were described
using mean and standard deviation for continuous variables
and proportions for categorical variables. Univariate analysis
of the association between low serum total testosterone level
and studied variables were assessed for statistical signiﬁcance,
using Chi-square tests or independent T-test, wherever appro-
priate. Multivariate logistic regression was used to assess the
factors associated with low testosterone level. A P-value of
<0.05 was considered statistically signiﬁcant.
3. Results
3.1. Participants’ characteristics
This study included a total of 1049 patients with type 2 diabe-
tes, aged between 30 and 70 years with a mean age (SD) of 52
(11.2) years. Their socio-demographic, clinical and relevant
characteristics are shown in Table 1. The mean (SD) of BMI
was 29.9 (5.2) kg/m2 with about 43.8% of diabetics being ob-
ese, and 39.3% overweight. About 28.7% had diabetes for
more than 10 years. More than half of the patients (58.7%)
were on combination of oral antidiabetic agents and insulin.
Most patients (88.3%) were on statins. Two thirds of the dia-
betic population (69.2%) was on antihypertensive treatment.3.2. Prevalence of low testosterone level
Table 2 shows the mean (SD) of serum gonadal hormone levels
among patients with type 2 diabetes mellitus, according to age.
The mean of serum gonadal hormone levels varied according
to age. It seems that total and free testosterone levels decreased
with increasing age.
Overall, 36.4% of patients with diabetes had total testoster-
one level <3 ng/ml and 29% of study participants had symp-
toms of androgen deﬁciency. The prevalence of low serum
total testosterone was 45% in age group 60–70 years, 37% in
age group 50–59 and 34.3% in age group 40–49 and 19.8%
in age group 30–39. Table 3 shows the prevalence of low serum
testosterone level (Total testosterone <3 ng/ml) for patients
with type 2 diabetes mellitus, according to the relevant charac-
teristics. Of those with serum testosterone level <3 ng/ml,
Table 2 The mean (SD) values of serum gonadal hormones level among patients with diabetes (n= 1049) according to age category.
Parameter 30–39 40–49 50–59 60–70 Total
Total testosterone (ng/ml) 4.6 (1.8) 3.8 (1.6) 3.8 (1.8) 3.4 (1.5) 3.8 (1.7)
Free testosterone (pg/ml) 11.8 (5.5) 10.3 (4.2) 9.7 (4.3) 7.8 (3.7) 9.6 (4.5)
Follicle stimulating hormone (MIU/ml) 7.7 (4.3) 7.4 (4.3) 8.5 (6.4) 10.6 (9.2) 8.8 (6.9)
Leuteinizing hormone (MIU/ml) 6.0 (2.3) 6.2 (2.7) 6.6 (3.9) 7.5 (4.8) 6.7 (3.9)
Sex hormone binding globulin (nmol/l) 39.1 (13.6) 36.2 (14.3) 38.0 (16.3) 37.2 (15.7) 37.5 (15.3)
Prolactin (ng/ml) 9.5 (7.1) 10.4 (8.2) 9.4 (6.1) 9.9 (6.6) 9.8 (6.9)
A.A. Alhayek et al.3480.2% had symptoms of androgen deﬁciency. About 16.9% of
those with serum testosterone level <3 ng/ml had primary
hypogonadism, and 83.1% had secondary hypogonadism.
3.3. Multivariate analysis of factors associated with low
testosterone level
In the multivariate analysis, the only variables that remained
signiﬁcantly associated with low serum total testosterone level
were age, income, body mass index and neuropathy (Table 4).
Compared to patients in the age group 30–39 years, patients
aged 40–49 years (OR = 1.89), 50–59 years (OR = 1.96),
and 60–69 years (OR = 2.57) were more likely to have low to-
tal testosterone level. Those who had a monthly income of less
than 500 JD were more likely to have low total testosterone le-
vel (OR = 1.76) than those who had a monthly income of
more than, or equal to 500 JD. Compared to patients with
obesity, those who had BMI <25 kg/m2, and those that were
overweight, were less likely to have low total testosterone level.
Diabetic neuropathy was associated with the increased odds of
low total testosterone level.4. Discussion
In the present study, 36.4% of patients with type 2 diabetes
had a total testosterone level of <3 ng/ml, and 29% of study
participants had symptoms of androgen deﬁciency. It is difﬁ-
cult to compare the study ﬁndings with those reported in other
studies, because of the differences in age of participants, cut-
points used to deﬁne hypogonadism, and duration and compli-
cation of diabetes.
In a large cohort of 574 men with type 2 diabetes with a
mean age of 65 and mean duration of diabetes of 10 years,
Mathis and his colleagues [17] found that 43% had total tes-
tosterone levels <10 nmol/l. In the United Kingdom, a
cross-sectional study of 355 men with type 2 diabetic aged
>30 showed that 17% of diabetic men had overt hypogonad-
ism with total testosterone <8 nmol/1, and a further 25% had
symptoms of hypogonadism associated with a total testoster-
one level of between 8 and 12 nmol/l [6]. In Spain, Corrales
et al. [18] used a combination of clinical and hormonal criteria
to deﬁne androgen deﬁciency and to analyze the relationship
between the androgen environment and glucose metabolism
in 55 type 2 diabetic men (63.6 ± 7.9 years, mean ± SD).
Low plasma levels of total testosterone (63.4 ng/ml) and free
testosterone (611 pg/ml) were found in 20% and 54.5% of dia-
betic men respectively. Another cross-sectional study from
Brazil showed that free and total testosterone levels were sub-
normal in 46% and 34% of diabetics, respectively [19].Of those with hypogonadism, 16.9% had primary hypogo-
nadism (LH> 10 MIU/ML) and 83.1% had secondary
hypogonadism (LH< 10 MIU/ML); suggesting that hypogo-
nadotropic hypogonadism is the predominant type of hypogo-
nadism in our diabetic subjects. This ﬁnding was not consistent
with the ﬁndings revealed by Ali et al. [11] who found high ser-
um and urinary FSH and LH among diabetics with low serum
total and serum free testosterone levels. However, Tenover
et al. [20] found that the majority of hypogonadal men over
the age of 60 had low, or inappropriately normal LH levels.
On the other hand, Chandel et al. [21] found that LH and
FSH concentrations in type 2 diabetic patients with low free
testosterone concentrations were in the normal range. Our
study reported a higher prevalence of hypogonadotropic hypo-
gonadism (low LH and FSH) levels than that reported by Ka-
poor et al. [6] who found that 7% had hypogonadotropic
hypogonadism and lower prevalence of primary hypogonad-
ism (high LH and FSH) levels which was seen in 26% of pa-
tients with type 2 diabetes compared to 16.9% of those who
were hypogonadal in our study who had a high level of LH.
A study carried out in Taiwan [22] showed that the prevalence
of both androgen deﬁciency and the prevalence of symptom-
atic androgen deﬁciency were 24.1% and 12%, respectively.
Both cross-sectional and longitudinal studies indicate that
testosterone levels decrease with age [23]. Our study showed
that total testosterone was inversely related to age. A higher
prevalence of low total testosterone was seen in men aged be-
tween 60 and 70 years, which is in agreement with the ﬁndings
of Grossmann et al. [17] who reported that 43% of men of the
same age had low total testosterone. Our ﬁndings were similar
to those of Corrales et al. [18] who found that the fraction of
diabetic men with a subnormal level of total testosterone in-
creased with age. Our ﬁndings were consistent with the ﬁnd-
ings revealed by Grossmann et al. [24] and Fukui et al. [25].
Grossmann et al. [24] found that those with low testosterone
levels were older than individuals with testosterone levels in
the normal range.
In agreement with previous studies [6,19,24,26–28], our
study showed a signiﬁcant association between BMI and low
serum total testosterone level. On the other hand, in a cross-
sectional study, Tripathy et al. [29], reported that there is no
relationship between total testosterone and BMI.
Regarding smoking, our study showed no signiﬁcant asso-
ciation between smoking and low testosterone levels in logistic
regression analysis. This result is in agreement with previously
published data [25,28,30].
Serum lipids were not signiﬁcantly associated with low total
testosterone in logistic regression analysis, a ﬁnding which is in
agreement with the ﬁndings of several other investigators who
reported no signiﬁcant correlation between serum lipids and
Table 3 Prevalence of low serum testosterone level (total
testosterone <3 ng/ml) for patients with type 2 diabetes
mellitus according to relevant characteristics.
Variable Total testosterone level P-value
P3 ng/ml <3 ng/ml
Age <0.005
30–39 138 (80.2) 34 (19.8)
40–49 151 (65.7) 79 (34.3)
50–59 182 (63.0) 107 (37.0)
60–70 192 (54.7) 159 (45.3)
Income <0.005
<500 290 (55.8) 230 (44.2)
P500 373 (71.5) 149 (28.5)
Education <0.005
Less than university 255 (56.3) 198 (43.7)
University 408 (69.3) 181 (30.7)
Body mass index (kg/m2) <0.004
<25 120 (70.6) 50 (29.4)
Overweight 276 (66.7) 138 (33.3)
Obese 267 (58.3) 191 (41.7)
Smoking
Non-smoker 179 (64.9) 97 (35.1) 0.004
Past-smoker 178 (58.0) 129 (42.0)
Current 306 (66.7) 379 (36.4)
Hypertension 0.055
Yes 536 (62.5) 322 (37.5)
No 127 (69.0) 57 (31.0)
Dyslipidemia 0.493
Yes 612 (63.7) 349 (36.3)
No 51 (63.0) 30 (37.0)
Diabetic retinopathy (DR) 0.002
No DR 249 (69.9) 107 (30.1)
Non proliferative DR 364 (61.7) 226 (38.3)
Proliferative DR 50 (52.1) 46 (47.9)
Diabetic nephropathy 0.070
Yes 217 (60.4) 142 (39.6)
No 446 (65.3) 237 (34.7)
Diabetic neuropathy <0.005
Yes 210 (54.4) 176 (45.6)
No 453 (69.1) 203 (30.9)
Duration of diabetes <0.005
65 years 339 (70.3) 143 (29.7)
6–10 years 168 (65.1) 90 (34.9)
>10 years 156 (51.7) 146 (48.3)
HbA1c
HbA1C 6 7 158 (70.5) 66 (29.5) 0.009
HbA1C> 7 505 (61.7) 313 (38.3)
Table 4 Multivariate analysis of factors associated with low
testosterone level.
Variable OR (95% CI) P-value
Age
30–39 1
40–49 1.89 (1.18, 3.04 0.008
50–59 1.96 (1.23, 3.10) 0.004
60–70 2.57 (1.63, 2.57) <0.005
Income
<500 1.76 (1.35, 2.29) <0.005
P500 1
Body mass index (kg/m2)
<25 kg/m2 0.73 (0.49, 1.08) 0.124
Overweight 0.71 (0.54, 0.95) 0.022
Obese 1
Diabetic neuropathy
Yes 1.39 (1.05, 1.84) 0.021
No 1
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that lower HDL cholesterol and higher triglyceride levels were
signiﬁcantly correlated with hypogonadism among diabetics
[17,31,32].
Serum testosterone levels have been reported to be lower in
men with hypertension [27]. The association observed between
serum total testosterone level and both systolic and diastolic
blood pressure was not signiﬁcant among our study partici-
pants. These ﬁndings are consistent with those reached by oth-
ers [30,31].In the present study, there was no signiﬁcant association be-
tween the serum testosterone level and HbA1c concentration.
This ﬁnding is consistent with the results obtained by other stud-
ies [24,33], while opposing what was found by Kapoor et al. [6].
Our ﬁndings also contradict the ﬁnding of the study undertaken
by Fukui et al. [34], who found that total testosterone concen-
trations correlated positively with HbA1c concentrations.
The association observed between hypogonadism and the
duration of diabetes was not signiﬁcant in our study. However,
this effect is difﬁcult to determine in patients with type 2 diabe-
tes. A plausible explanation for this is that type 2 diabetes may
be silent for many years before clinical recognition. This ﬁnding
is consistent with data from a number of studies [5,25,33].
Surprisingly, in the present study, we found a statistically
signiﬁcant association between monthly income and hypogo-
nadism. This ﬁnding is consistent with work done by Susan
et al. [35]. A possible explanation for this association is that
a monthly income of less than 500 JDs may function as a mar-
ker for poorer health access, increased stress, adverse health
behaviors, and impoverished neighborhood environment.
Wong et al. [36] found that having a lower personal income
was independently associated with the increased risk of having
androgen deﬁciency.
A signiﬁcant association between low testosterone level and
the presence of diabetic neuropathy was found in this study.
These results are in agreement with previously published data
[17,25]. Ali et al. [11] reported a signiﬁcantly low serum total
testosterone level in the neuropathic diabetic patients.
Several limitations have to be considered in the interpreta-
tion of this study. This is a cross-sectional design, making it
impossible to determine the causality of whether the diabetes
preceded or followed the decline in serum testosterone level.
In conclusion, given the large numbers of individuals with
diabetes in Jordan, the number of diabetic patients with low
serum testosterone is undoubtedly enormous. This urgently
calls for implementing early, universal screening programs,
irrespective of the symptoms of androgen deﬁciency, in order
to detect those who have low serum total testosterone level
at any early stage and to supplement testosterone accordingly.
We recommend screening all type 2 diabetics for androgen
A.A. Alhayek et al.36levels in health care settings, and referring them to endocrinol-
ogists accordingly, as well as establishing a hormonal base line
for patients with type 2 diabetes to compare with in the future.
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